Compare Nomura Holdings Inc (NMR) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Novavax Inc — how do they compare? Nomura Holdings Inc trades at $9.8 (market cap $28.69B), while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: Nomura Holdings Inc is far larger — about 22.1× Novavax Inc's market cap, and Nomura Holdings Inc pays a 3.3% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NMR | NVAX | |
|---|---|---|
Market Cap | $28.69B | $1.30B |
Sector | Financials | Health |
52-Week High | $10.04 | $11.19 |
52-Week Low | $6.73 | $6.22 |
Dividend Yield | 3.3% | — |
Enterprise Value | — | $879.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.95, up 0.3% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 11.77 and net income margin of 20.4%, supported by record annual profit in 2025. Recent Q2 2026 earnings beat expectations, and revenue growth trends upward, though cash flow from operations remains negative.
Outlook is positive with valuation appeal and earnings momentum, but risks include volatile cash flows, high debt levels, and reliance on wholesale revenue. Analysts are mixed, with 33% buy ratings. The stock presents a value opportunity amid bullish technicals, yet investors should weigh debt concerns against growth prospects.
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
